Indication
Philadelphia chromosome positive acute lymphoblastic leukemia
Philadelphia chromosome-positive acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the malignant proliferation of immature lymphoid precursor cells, primarily of B-cell lineage, within the bone marrow and peripheral blood. Read more about Philadelphia chromosome positive acute lymphoblastic leukemia
45 drugs 38 manufacturers
Drugs that treat it
Common Philadelphia chromosome positive acute lymphoblastic leukemia therapies.
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
ICLUSIG (ponatinib HCl)
IMATINIB (imatinib mesylate)
IMATINIB (imatinib mesylate)
IMATINIB (imatinib mesylate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPhiladelphia chromosome-positive acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the malignant proliferation of immature lymphoid precursor cells, primarily of B-cell lineage, within the bone marrow and peripheral blood.
It is pathologically defined by the t(9;22)(q34;q11.2) reciprocal chromosomal translocation that creates the Philadelphia chromosome, generating the oncogenic BCR::ABL1 fusion gene and producing a constitutively active tyrosine kinase that drives dysregulated cell proliferation and survival.
While occurring in both pediatric and adult populations, its incidence increases markedly with age, representing roughly one-fourth of adult cases.
Patients typically present with systemic features of bone marrow failure, including anemia, thrombocytopenia, recurrent infections, fatigue, bleeding, and potential extramedullary involvement.
- cancer.gov
Philadelphia chromosome-positive acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the malignant proliferation of immature lymphoid precursor cells, primarily of B-cell lineage, within the bone marrow and peripheral blood While occurring in both pediatric and adult populations, its incidence increases markedly with age, representing roughly one-fourth of adult cases Patients typically present with systemic features of bone marrow failure, including anemia, thr...
- cancergeneticslab.ca
Philadelphia chromosome-positive acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the malignant proliferation of immature lymphoid precursor cells, primarily of B-cell lineage, within the bone marrow and peripheral blood It is pathologically defined by the t(9;22)(q34;q11.2) reciprocal chromosomal translocation that creates the Philadelphia chromosome, generating the oncogenic BCR::ABL1 fusion gene and producing a constitutively active tyrosine kinase that dr...
- nih.gov
It is pathologically defined by the t(9;22)(q34;q11.2) reciprocal chromosomal translocation that creates the Philadelphia chromosome, generating the oncogenic BCR::ABL1 fusion gene and producing a constitutively active tyrosine kinase that drives dysregulated cell proliferation and survival
- iclusig.com
It is pathologically defined by the t(9;22)(q34;q11.2) reciprocal chromosomal translocation that creates the Philadelphia chromosome, generating the oncogenic BCR::ABL1 fusion gene and producing a constitutively active tyrosine kinase that drives dysregulated cell proliferation and survival
- nih.gov
While occurring in both pediatric and adult populations, its incidence increases markedly with age, representing roughly one-fourth of adult cases
- stbaldricks.org
Patients typically present with systemic features of bone marrow failure, including anemia, thrombocytopenia, recurrent infections, fatigue, bleeding, and potential extramedullary involvement
- yalemedicine.org
Patients typically present with systemic features of bone marrow failure, including anemia, thrombocytopenia, recurrent infections, fatigue, bleeding, and potential extramedullary involvement
Personalize your experience
Follow Philadelphia chromosome positive acute lymphoblastic leukemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.